NEW YORK, Oct. 2 /PRNewswire/ -- InterCure Ltd., a medical device company publicly traded on the Tel-Aviv Stock Exchange (TASE: INCR), today announced its website is ranked first in the Health and Medical category for the Pharmaceutical and Medical Products online industry based on the market share of U.S. visits received for January through March 2008.
Advertisement
The Hitwise U.S. Top 10 Awards Program celebrates the most successful U.S. websites in 160+ online industries. As Hitwise reports on the anonymous online usage and search behavior of more than 10 million U.S. Internet users--the largest online sample of its kind--this unique awards program recognizes excellence in online performance through public popularity.
Advertisement
Ranked second last quarter, RESPeRATE.com now tops the list including a number of well known and established health brand websites recognized by Hitwise such as Merck, Alli, Colgate, Davis Vision and Nexium.
"As RESPeRATE expands into the retail market, there is a new buzz surrounding our innovative hypertension treatment device. The ever-increasing consumer traffic to our website is a great barometer of market demand," said Erez Gavish, president and CEO of InterCure. "Being at the top of a list that includes some of the biggest names in the healthcare industry is certainly indicative of our own success as well as a continued and growing interest in natural therapies such as RESPeRATE."
About InterCure Ltd. and RESPeRATE
InterCure Ltd. (Tel-Aviv Stock Exchange: INCR) is disrupting the $42 billion hypertension industry with the world's first FDA-cleared, OTC blood pressure treatment device, RESPeRATE(R) (www.resperate.com). In a market where seven out of 10 hypertensives are NOT controlled despite the availability of more than 100 blood pressure medications, RESPeRATE provides an effective non-drug therapy with no side effects.
RESPeRATE has gained widespread support of hypertension specialists and has secured regulatory clearance in most key international markets. Ten separate clinical studies have proven the device's efficacy and safety, and RESPeRATE is now featured in more than 20 popular and professional text books.
With more than 100,000 units sold, thousands of supportive clinicians worldwide and one of the world's most popular hypertension websites, InterCure is now introducing RESPeRATE into retail pharmacies to increase access to hypertension sufferers.
InterCure has an exciting product pipeline based on its broadly-patented "Device-Guided Breathing" technology platform. This technology enables a systematic reduction in sympathetic outflow of the autonomic nervous system, one of the key underlying causes of cardiovascular disease, insomnia and several other medical conditions.
About Hitwise
Hitwise is the leading online competitive intelligence service. Only Hitwise provides its 1,400 clients around the world with daily insights on how their customers interact with a broad range of competitive websites, and how their competitors use different tactics to attract online customers.
Since 1997, Hitwise has pioneered a unique, network-based approach to Internet measurement. Through relationships with ISPs around the world, Hitwise's patented methodology anonymously captures the online usage, search and conversion behavior of 25 million Internet users. This unprecedented volume of Internet usage data is seamlessly integrated into an easy to use, web-based service, designed to help marketers better plan, implement and report on a range of online marketing programs.
Hitwise, a subsidiary of Experian (FTS: EXPN) www.experiangroup.com operates in the United States, United Kingdom, Australia, New Zealand, Hong Kong and Singapore. More information about Hitwise is available at www.hitwise.com.
For up to date analysis of online trends, please visit the Hitwise Intelligence-Analyst Weblogs at http://weblogs.hitwise.com and the Hitwise Data Center at www.hitwise.com/datacenter.
Forward-Looking Statements
This news release may contain forward-looking statements that are based on the Company's current beliefs and assumptions and on information currently available to its management. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. As a result of these risks, uncertainties and other factors, readers are cautioned not to place undue reliance on any forward-looking statements included in this press release. These forward-looking statements represent beliefs and assumptions only as of the date of this news release, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.
Contacts: Lisa Mokaba Brian Packard Schwartz Communications InterCure, Inc. +1-781-684-0770 +1-646-652-5800 x.7134 [email protected] [email protected]
SOURCE InterCure Ltd.
